NJNathan T. James

Nathan T. James

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nathan T. James has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Population pharmacokinetic analysis of dexmedetomidine in children using real‐world data from electronic health records and remnant specimens

    by Nathan T. James, Joseph H. Breeyear, Richard Caprioli, Todd Edwards, Brian Hachey, Prince J. Kannankeril, Jacob M. Keaton, Matthew D. Marshall, Sara L. Van Driest, Leena Choi

    Aims: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and electronic health records (EHRs) and explore the impact of patient's characteristics and pharmacogenetics on dexmedetomidine clearance.Methods: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed‐effects modelling. Stage 1 developed a model without genotype variables; Stage 2 added pharmacogenetic effects.Results: Our final study population included 354 post‐cardiac surgery patients aged 0–22 years (median 16 mo). The data were best described with a 2‐compartment model with allometric scaling for weight and Hill maturation function for age. Population parameter estimates and 95% confidence intervals were 27.3 L/h (24.0–31.1 L/h) for total clearance, 161 L (139–187 L) for central compartment volume of distribution, 26.0 L/h (22.5–30.0 L/h) for intercompartmental clearance and 7903 L (5617–11 119 L) for peripheral compartment volume of distribution. The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5–42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99–7.08). Genotype was not statistically or clinically significant.Conclusion: Our study demonstrates the use of real‐world EHR data and remnant specimens to perform a population pharmacokinetic analysis and investigate covariate effects in a large paediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score.


  • Open Access

    Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real World Data from Electronic Health Records and Remnant Specimens

    by Nathan T. James, Joseph H. Breeyear, Richard Caprioli, Todd Edwards, Brian Hachey, Prince J. Kannankeril, Jacob M. Keaton, Matthew D. Marshall, Sara L. Van Driest, Leena Choi

    Aim: Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and data from electronic health records (EHRs) and explore the impact of patient’s characteristics and pharmacogenetics on dexmedetomidine clearance. Methods: Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed-effects modeling. The first stage developed a model without genotype variables; the second stage added pharmacogenetic effects. Results: Our final study population included 354 post-cardiac surgery patients age 0 to 22 years (median 16 months). The final two-compartment model included allometric weight scaling and age maturation. Population parameter estimates and 95% confidence intervals were 27.3 L/hr (24.0 – 31.1 L/hr) for total clearance (CL), 161 L (139 – 187 L) for central compartment volume of distribution (V 1 ), 26.0 L/hr (22.5 – 30.0 L/hr) for intercompartmental clearance (Q), and 7903 L (5617 – 11119 L) for peripheral compartment volume of distribution (V 2 ). The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5 – 42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99 – 7.08). Genotype was not statistically or clinically significant. Conclusion: Our study demonstrates the use of real-world EHR data and remnant specimens to perform a population PK analysis and investigate covariate effects in a large pediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score. What is already known about this subject: ∘ Previous dexmedetomidine pharmacokinetic (PK) studies in pediatric populations have limited sample size. ∘ Smaller studies present a challenge for identifying covariates that may impact individual PK profiles. What this study adds: ∘ We performed a dexmedetomidine population PK study with a large pediatric cohort using data obtained from electronic health records and remnant plasma specimens to enable increased sample size. ∘ xsDifferences in PK due to UGT1A4 or UGT2B10 variants or CYP2A6 risk score are not clinically impactful for this population.


  • Building longitudinal medication dose data using medication information extracted from clinical notes in electronic health records

    by Elizabeth McNeer, Cole Beck, Hannah L Weeks, Michael L Williams, Nathan T James, Cosmin A Bejan, Leena Choi

    Objective: To develop an algorithm for building longitudinal medication dose datasets using information extracted from clinical notes in electronic health records (EHRs). Materials and Methods: We developed an algorithm that converts medication information extracted using natural language processing (NLP) into a usable format and builds longitudinal medication dose datasets. We evaluated the algorithm on 2 medications extracted from clinical notes of Vanderbilt’s EHR and externally validated the algorithm using clinical notes from the MIMIC-III clinical care database. Results: For the evaluation using Vanderbilt’s EHR data, the performance of our algorithm was excellent; F1-measures were ≥0.98 for both dose intake and daily dose. For the external validation using MIMIC-III, the algorithm achieved F1-measures ≥0.85 for dose intake and ≥0.82 for daily dose. Discussion: Our algorithm addresses the challenge of building longitudinal medication dose data using information extracted from clinical notes. Overall performance was excellent, but the algorithm can perform poorly when incorrect information is extracted by NLP systems. Although it performed reasonably well when applied to the external data source, its performance was worse due to differences in the way the drug information was written. The algorithm is implemented in the R package, “EHR,” and the extracted data from Vanderbilt’s EHRs along with the gold standards are provided so that users can reproduce the results and help improve the algorithm. Conclusion: Our algorithm for building longitudinal dose data provides a straightforward way to use EHR data for medication-based studies. The external validation results suggest its potential for applicability to other systems.


  • EHR: Electronic Health Record (EHR) Data Processing and Analysis Tool

    by Leena Choi, Cole Beck, Hannah Weeks, Elizabeth McNeer, Nathan James, Michael Williams